Skip to main content
. 2023 Jun 1;11(6):1610. doi: 10.3390/biomedicines11061610

Figure 1.

Figure 1

Effector mechanisms of therapeutic mAbs in cancer therapy. (A) Signaling pathway blocking. (B) Antibody-dependent cellular cytotoxicity. (C) Complement-dependent cytotoxicity. (D) Antibody-dependent cellular phagocytosis. AKT: Protein kinase B, ERK: extracellular signal-regulated kinase, C1q: complement component 1q, MAC: Membrane attack complex, FcγRIII: Fc-gamma receptor III, FcγRI: Fc-gamma receptor I. Image created in BioRender (www.biorender.com, accessed on 20 January 2023).